Sugi Predict

Sugi Predict / Compounds / SCHEMBL3011817

SCHEMBL3011817

SCHEMBL3011817

O=C(Nc1cnccn1)[C@@H]1C[C@@H](F)CN1c1nc(Cl)nc(Nc2cc(C3CC3)n[nH]2)n1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 11/20 0.45
▸ PDE10A Q9Y233 1/20 0.33
▸ KARS1 Q15046 1/20 0.33
▸ EP300 Q09472 2/20 0.33
▸ CREBBP Q92793 2/20 0.33
▸ MAP4K1 Q92918 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ CCNE2 O96020 1/20 0.32
▸ CCNE1 P24864 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ POLB P06746 2/20 0.31
▸ MAPT P10636 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3000073 0.92 IGF1R (0.54) IGF1RPDE10AKARS1CCNE2CCNE1
SCHEMBL3010556 0.89 IGF1R (0.43) IGF1RPDE10AKARS1GSK3BDYRK1A
SCHEMBL3684352 0.89 IGF1R (0.44) IGF1RPDE10AKARS1MAP4K1KDM4E
SCHEMBL3005666 0.89 IGF1R (0.44) IGF1RPDE10AKARS1MAP4K1KDM4E
SCHEMBL3008568 0.88 IGF1R (0.42) IGF1RMEN1KMT2AGSK3BDYRK1A
SCHEMBL3005593 0.88 IGF1R (0.41) IGF1RPDE10AKARS1KDM4EMEN1
SCHEMBL3005579 0.88 IGF1R (0.41) IGF1RPDE10AKARS1KDM4EMEN1
SCHEMBL3013967 0.88 IGF1R (0.42) IGF1RPDE10AKARS1MAPTGSK3B
SCHEMBL13225962 0.87 IGF1R (0.41) IGF1RKARS1KDM4EMEN1RAB9A
SCHEMBL11967765 0.86 IGF1R (0.41) IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415340-B2 Triazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 — — US disclosed
US-8415340-B2 Triazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 — — US disclosed
US-8415340-B2 Triazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 — — US disclosed
EP-2175933-B1 TRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-08-22 — — EP disclosed
US-20100197654-A1 TRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-05 — — US disclosed
US-20100197654-A1 TRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-05 — — US disclosed
US-20100197654-A1 TRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-05 — — US disclosed
WO-2009015254-A1 TRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197654-A1 TRIAZINE KINASE INHIBITORS ABL1, STK25, FLT3 IGF1R 688/4885PDE10A 2420/4885KARS1 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.